Event Already in Full Capacity

For Delegate Please Press Request to Join and one of our project manager will contact you!

08
November

08:00 AM EST

Medicinal Chemistry

Name: Medicinal Chemistry Strategy Meeting Boston
Start: 2023-11-16T08:00
End: 2023-11-16T17:50
Location: Le Méridien Boston Cambridge

Strategy Meeting East Coast USA 2023

Reinvigorating Productivity in Pharma Biotech Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2023 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Aaron Frank

Director and Head of Computational Chemistry Arrakis Therapeutics

Allen Hopper

Senior Director of Drug Discovery Lucy Therapeutics

Andrew L. Roughton, Ph.D

WuXi AppTec Co., Ltd.

Blaise Lippa

SVP, Molecular Discovery Morphic Therapeutics

Byron DeLaBarre

Chief Technology Officer (CTO) & Head of Platform Pin Therapeutics

Carlos Pedraza

Associate Vice President and Head of Biology (US) Sai Life Science

Ching Kim Tye

mRNA Director, LNP Platform Development Sanofi

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Dominic Reynolds

Senior Vice President, Head of Drug Discovery Remix Therapeutics

Dr. Tamsin Mansley

President and Global Head of Application Science Optibrium Inc.

Ed Olhava

Senior Vice President, Preclinical Development IFM Therapeutics

Over his nearly 20 year career in mid and early-stage biotech, Ed Olhava has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities.
Before joining <a href="https://www.ifmthera.com/">IFM</a>, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme’s first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924.
Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.

Horst Hemmerle

Chief Scientific Officer Kojin Therapeutics

Ivan Efremov

VP, Head of Medicinal Chemistry Nereid Therapeutics

Jacques Dumas

Chief Scientific Officer Arrakis Therapeutics

Jacques Dumas has 30-years experience in drug discovery and development. He is a co-inventor of two marketed drugs in Oncology, Nexavar® and Stivarga®.In January 2020, Jacques joined Arrakis, a biotech company dedicated to the discovery of small molecules targeting RNA. He is currently Chief Scientific Officer (CSO) and oversees all R&D functions. From 2015 to 2019, Jacques was CSO at Tetraphase, focusing on fully synthetic tetracyclines (acquired by La Jolla in 2020) and played a key role in regulatory approvals of eravacycline, a broad-spectrum antibiotic. Before joining Tetraphase, Jacques was CSO at Idenix (acquired by Merck in 2014) working on liver-targeted nucleosides and their applications in virology and oncology. From 2007 to 2014, Jacques worked at AstraZeneca, most recently as VP of Strategy, Infectious Diseases. Prior to that he spent 15 years at Bayer Healthcare. Jacques holds a Ph.D. in Organic Chemistry from Paris VI University and completed a Post-doctoral Fellowship at Stanford University.

Kaicheng Zhu

Head of Operations, Boston Bellen

Kevin Kreutter

Vice President, Drug Discovery Empress Therapeutics

Liang Mao

Senior Director, Head of Developability and Formulation Research WuXi AppTec

Matthew Lucas

VP of Medical Chemistry Third Harmonic Bio

Norman Azoulay

Director – Scientific Products Excelra

Onur Atasoylu

Director, Head of Computational Chemistry Incyte

Richard Heidebrecht

Vice President and R&D Glycologix

Robert Goodnow

Head Drug Discovery Sciences Takeda

Sam Baskaran

Director, Medicinal Chemistry WuXi AppTec

Sejal Patel

Vice President Chemistry Scorpion Therapeutics

Sejal is an entrepreneurial and data driven scientific leader who has two decades of drug discovery experience from concept to clinic. She is currently a Vice President of Chemistry at Scorpion Therapeutics, where she has been co-leading the early drug discovery portfolio, prioritizing and enabling novel targets using the company’s chemoproteomics, and covalent library platform towards lead optimization via integration of advanced technologies and scientific rigor. Prior to joining Scorpion, Sejal worked at Novartis Institute for Biomedical Research (NIBR) in global discovery chemistry where she led integrated drug discovery teams from early target validation to identification of clinical leads across multiple therapeutic areas, as well as supporting IND-enabling studies and filings. Sejal also has experience in portfolio strategy, delivery technologies, digital therapeutics, academic/biotech collaborations, and strategic partnerships. Sejal has been a long-standing advocate of mentorship programs to share experiences, and to level up inclusivity in the sciences. Sejal received her dual B.S. degrees in chemistry and biology from UC Irvine and her Ph.D. degree in organic chemistry from MIT under the supervision of Tim Jamison.

Shankar Venkatraman

Executive Director, Chemistry IFM Therapeutics

Over his 20+ year industrial career Shankar Venkatraman has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, and safety to enter clinical trials with these novel entities. Before joining IFM Therapeutics, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by the end of 2023. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axys Pharmaceuticals, and worked on cathepsin K, with efforts leading to the identification of Odanacatib. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.

Sonela Cavicke

Vice President of Discovery Business Development Sai Life Sciences Ltd

Xiaoqi (Charles) Chen

VP of Business Development Bellen Chemistry

See the full agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

AI/ML
Evaluating the Effectiveness of Computer-Aided Drug Design, Artificial Intelligence and Machine Learning Tools In Fragment-Based Lead Discovery
-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

INNOVATIVE AND EMERGING MODALITIES
Building Successful Collaborations in Drug Discovery: Strategies for Effective Partnerships
-Richard Heidebrecht
Vice President and R&D
Glycologix

CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Next-Generation PROTACs: Beyond Traditional Ubiquitin Ligases
-Byron DeLaBarre
Chief Technology Officer (CTO) & Head of Platform
Pin Therapeutics

HIT IDENTIFICATION / LEAD OPTIMIZATION
Leveraging Predictive Model Techniques To Accelerate Hit-To Lead Optimization
-Onur Atasoylu
Director, Head of Computational Chemistry
Incyte

INTEGRATED DRUG DISCOVERY
Challenges of the CNS Drug Discovery and Development
-Alex Nivorozhkin
Chief Scientific Officer
Cybin

DESIGN & SYNTHESIS
Emerging Trends in Medicinal Chemistry: Small Molecule Analog Synthesis and Structure-Activity Relationship (SAR) Strategies
-Matthew Lucas
VP of Medical Chemistry
Third Harmonic Bio

11:10 – 12:10

Roundtable Tracks

AI/ML
Overcoming Challenges And Achieving Resilience: The Future of Biotech and Biopharma – AI-Guided In Drug Discovery and Development (Topic TBC)

INNOVATIVE AND EMERGING MODALITIES
Novel Chemical Modalities
-Sonela Cavicke
Vice President of Discovery Business Development
Sai Life Sciences Ltd

CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Approaches to ‘Undruggable’ Targets – Targeted Protein Degradation, Chemical Biology and beyond
-Andrew L. Roughton, Ph.D
WuXi AppTec Co., Ltd.

HIT IDENTIFICATION / LEAD OPTIMIZATION
RNA Therapeutics Beyond Antivirals
-Carlos Pedraza
Associate Vice President and Head of Biology (US)
Sai Life Science

INTEGRATED DRUG DISCOVERY
Strategies for implementation of modern and innovative integrated drug discovery towards emerging drug modalities
-Sam Baskaran
Director, Medicinal Chemistry
WuXi AppTec

DESIGN & SYNTHESIS
Efficient Hit-to-Lead Design, Synthesis, and Screening Strategies for Drug Discovery

12:15 – 13:15

Roundtable Tracks

AI/ML
Strategic Partnerships in the Age of AI/ML: Maximizing Value through Collaboration
-Robert Goodnow
Head Drug Discovery Sciences
Takeda

INNOVATIVE AND EMERGING MODALITIES
Advancing Drug Discovery: Exploring Innovative Modalities with Small Molecules in Pre-clinical Development
-Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics

CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION & UNDRUGGABLES
Tackling Drug Resistance and Undruggable Targets
-Sejal Patel
Vice President Chemistry
Scorpion Therapeutics

HIT IDENTIFICATION / LEAD OPTIMIZATION
Investigating Best Strategies To Accelerate The Progress of Compounds From Hit Identification Into Lead Optimization
-Ivan Efremov
VP, Head of Medicinal Chemistry
Nereid Therapeutics

INTEGRATED DRUG DISCOVERY
Translation Gap: Challenges in Translating Promising Drug Candidates to Clinical Success
-Blaise Lippa
SVP, Molecular Discovery
Morphic Therapeutics

DESIGN & SYNTHESIS
SAR Considerations for CNS-Active Small Molecules: Strategies and Challenges
-Allen Hopper
Senior Director of Drug Discovery
Lucy Therapeutics

15:15 – 16:15

Roundtable Tracks

AI/ML
The Practical Application Of AI To Drug Discovery: What’s Required For Success
-Dr. Tamsin Mansley
President and Global Head of Application Science
Optibrium Inc.

INNOVATIVE AND EMERGING MODALITIES
The Most Recent Advancements in Small Molecule Drug Design, Development, and Synthesis In Drug Bioavailability

CHEMICAL BIOLOGY AND UNDRUGGABLES
Moving Towards the Clinic: Preclinical PK and Safety Studies of PROTACs in Targeted Protein Degradation

HIT IDENTIFICATION / LEAD OPTIMIZATION
Rethinking Drug Design & Discovery in the Era of Generative AI
-Norman Azoulay
Director – Scientific Products
Excelra

INTEGRATED DRUG DISCOVERY
Collaborative Platforms for Drug Discovery: Enabling Data Sharing and Collaboration

DESIGN & SYNTHESIS
Using An Integrated CRO/CDMO Service To Accelerate Drug Discovery And Development
-Kaicheng Zhu
Head of Operations, Boston
Bellen

16:30 – 17:30

Roundtable Tracks

AI/ML
Harnessing AI/ML in RNA Modeling and Cheminformatics: From Sequence Analysis to Drug Design
-Aaron Frank
Director and Head of Computational Chemistry
Arrakis Therapeutics

INNOVATIVE AND EMERGING MODALITIES
The Most Recent Advancements in Small Molecule Drug Design, Development, and Synthesis in Drug Bioavailability
-Kevin Kreutter
Vice President, Drug Discovery
Empress Therapeutics

CHEMICAL BIOLOGY AND UNDRUGGABLES
Utilizing The New Warheads: Strategic Ways Of Developing Targeted Covalent Drugs
-Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

HIT IDENTIFICATION / LEAD OPTIMIZATION
Supercharging Drug Discovery: Accelerating Hit Identification and Lead Optimization for Rapid Development
-Horst Hemmerle
Chief Scientific Officer
Kojin Therapeutics

INTEGRATED DRUG DISCOVERY
RNA-Targeted Drug Discovery: Advances in Hit Identification and Lead Optimization Strategies
-Dominic Reynolds
Senior Vice President, Head of Drug Discovery
Remix Therapeutics

DESIGN & SYNTHESIS
Lipid Nanoparticles (LNPs) in Medicinal Chemistry: Synthesis, Formulation, and Delivery Optimization
-Ching Kim Tye
mRNA Director, LNP Platform Development
Sanofi

Reasons To Attend the Strategy Meeting

Discussions on the advancements in targeted protein degradation andrnpushing past its boundaries.

Leveraging Artificial Intelligence and Machine Learning in accelerating therndevelopment of new drugs

Discuss approaches to further understand the interactions of undruggablerntargets and different Protein Degraders such as PROTACs, Molecular Glues,rnetc

Focusing on advancing interrogative techniques to improve the Drug Delivery System/Discovery: Modified mRNA, Nanoparticle-Mediated siRNA, Antibody-Drug Conjugates, and more

Become an official strategy meeting partner Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

Hotel & Venue

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT’s elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand’s European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details Maps & Direction Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Event Already in Full Capacity

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Drug Discovery Biology Strategy Meeting East Coast – Boston 2024

Medicinal Chemistry

Strategy Meeting East Coast USA 2023

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2023 Facilitators

Aaron Frank

Allen Hopper

Andrew L. Roughton, Ph.D

Blaise Lippa

Byron DeLaBarre

Carlos Pedraza

Ching Kim Tye

Diane Joseph-McCarthy

Dominic Reynolds

Dr. Tamsin Mansley

Ed Olhava

Horst Hemmerle

Ivan Efremov

Jacques Dumas

Kaicheng Zhu

Kevin Kreutter

Liang Mao

Matthew Lucas

Norman Azoulay

Onur Atasoylu

Richard Heidebrecht

Robert Goodnow

Sam Baskaran

Sejal Patel

Shankar Venkatraman

Sonela Cavicke

Xiaoqi (Charles) Chen

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Medicinal Chemist

Computational Chemist

Translational

Chemist/Biology

In-Silico/In-vivo/In-vitro Chemist/Biologist

Chemical Biology

Molecular Chemist/Biologist

Hit and Lead Chemist

Small/Large Molecules Chemist

Drug Discovery or Drug Development

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATION

Roundtable

Roundtable Tracks

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

Roundtable

Roundtable Tracks

NETWORKING LUNCH

AFTERNOON KEYNOTE PRESENTATION

Le Meridien Cambridge Boston